623 related articles for article (PubMed ID: 17434105)
21. Patterns of local failure following prostate brachytherapy.
Stone NN; Stock RG; White I; Unger P
J Urol; 2007 May; 177(5):1759-63; duscussion 1763-4. PubMed ID: 17437808
[TBL] [Abstract][Full Text] [Related]
22. Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation.
Orio P; Wallner K; Merrick G; Herstein A; Mitsuyama P; Thornton K; Butler W; Sutlief S
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):342-6. PubMed ID: 17236959
[TBL] [Abstract][Full Text] [Related]
23. The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy.
Potters L; Huang D; Fearn P; Kattan MW
Brachytherapy; 2003; 2(1):26-31. PubMed ID: 15062160
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.
Macdonald OK; D'Amico AV; Sadetsky N; Shrieve DC; Carroll PR
Urology; 2007 Jul; 70(1):106-10. PubMed ID: 17656218
[TBL] [Abstract][Full Text] [Related]
25. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.
Moul JW; Connelly RR; Lubeck DP; Bauer JJ; Sun L; Flanders SC; Grossfeld GD; Carroll PR
J Urol; 2001 Oct; 166(4):1322-7. PubMed ID: 11547066
[TBL] [Abstract][Full Text] [Related]
26. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
[TBL] [Abstract][Full Text] [Related]
27. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
29. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
D'Amico AV; Cote K; Loffredo M; Renshaw AA; Chen MH
J Urol; 2003 Apr; 169(4):1320-4. PubMed ID: 12629352
[TBL] [Abstract][Full Text] [Related]
30. Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE.
Litwin MS; Sadetsky N; Pasta DJ; Lubeck DP
J Urol; 2004 Aug; 172(2):515-9. PubMed ID: 15247718
[TBL] [Abstract][Full Text] [Related]
31. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
[TBL] [Abstract][Full Text] [Related]
32. 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial.
Wallner K; Merrick G; True L; Sherertz T; Sutlief S; Cavanagh W; Butler W
Radiother Oncol; 2005 Jun; 75(3):307-10. PubMed ID: 16086912
[TBL] [Abstract][Full Text] [Related]
33. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE.
Ryan CJ; Elkin EP; Small EJ; Duchane J; Carroll P
Urol Oncol; 2006; 24(5):396-402. PubMed ID: 16962488
[TBL] [Abstract][Full Text] [Related]
34. A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone.
Papagikos MA; Rossi PJ; Urbanic JJ; deGuzman AF; McCullough DL; Clark PE; Lee WR
Am J Clin Oncol; 2007 Apr; 30(2):199-204. PubMed ID: 17414471
[TBL] [Abstract][Full Text] [Related]
35. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience.
Sylvester JE; Grimm PD; Blasko JC; Millar J; Orio PF; Skoglund S; Galbreath RW; Merrick G
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):57-64. PubMed ID: 17084544
[TBL] [Abstract][Full Text] [Related]
36. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.
Cooperberg MR; Broering JM; Litwin MS; Lubeck DP; Mehta SS; Henning JM; Carroll PR;
J Urol; 2004 Apr; 171(4):1393-401. PubMed ID: 15017184
[TBL] [Abstract][Full Text] [Related]
37. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
38. Effect of family history on outcomes in patients treated with definitive brachytherapy for clinically localized prostate cancer.
Peters CA; Stock RG; Blacksburg SR; Stone NN
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):24-9. PubMed ID: 18692325
[TBL] [Abstract][Full Text] [Related]
39. Predictors of metastatic disease after prostate brachytherapy.
Forsythe K; Burri R; Stone N; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):645-52. PubMed ID: 22137025
[TBL] [Abstract][Full Text] [Related]
40. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
